Skip navigation
Universidade de Brasília
Veuillez utiliser cette adresse pour citer ce document : http://repositorio.unb.br/handle/10482/44333
Fichier(s) constituant ce document :
Il n'y a pas de fichiers associés à ce document.
Affichage complet
Élément Dublin CoreValeurLangue
dc.contributor.authorMota, Isabela Ferreira Lima-
dc.contributor.authorLima, Larissa S. de-
dc.contributor.authorSantana, Bruna de M.-
dc.contributor.authorGobbo, Giovanna de A. M.-
dc.contributor.authorBicca, João V. M. L.-
dc.contributor.authorAzevedo, Juliana R. M.-
dc.contributor.authorVeras, Letícia G.-
dc.contributor.authorTaveira, Rodrigo de A. A.-
dc.contributor.authorPinheiro, Gabriela B.-
dc.contributor.authorMortari, Márcia Renata-
dc.date.accessioned2022-07-27T20:08:22Z-
dc.date.available2022-07-27T20:08:22Z-
dc.date.issued2021-05-21-
dc.identifier.citationMOTA, Isabela F. L. et al. Alzheimer’s disease: innovative therapeutic approaches based on peptides and nanoparticles. The Neuroscientist, maio 2021. DOI 10.1177/10738584211016409. Disponível em: https://journals.sagepub.com/doi/10.1177/10738584211016409. Acesso em: 27 jul. 2022.pt_BR
dc.identifier.urihttps://repositorio.unb.br/handle/10482/44333-
dc.language.isoInglêspt_BR
dc.publisherSAGE Journalspt_BR
dc.rightsAcesso Restritopt_BR
dc.titleAlzheimer’s disease : innovative therapeutic approaches based on peptides and nanoparticlespt_BR
dc.typeArtigopt_BR
dc.subject.keywordAlzheimer, Doença dept_BR
dc.subject.keywordPeptídeospt_BR
dc.subject.keywordVenenos - proteínas - peptídeospt_BR
dc.subject.keywordNanopartículaspt_BR
dc.identifier.doihttps://doi.org/10.1177/10738584211016409pt_BR
dc.relation.publisherversionhttps://journals.sagepub.com/doi/10.1177/10738584211016409pt_BR
dc.description.abstract1Alzheimer’s disease (AD) is the main cause of dementia in the world and its etiology is not yet fully understood. The pathology of AD is primarily characterized by intracellular neurofibrillary tangles and extracellular amyloid-β plaques. Unfortunately, few treatment options are available, and most treat symptoms, as is the case of acetylcholinesterase inhibitors (IAChE) and N-methyl-d-aspartate receptor antagonists. For more than 20 years pharmaceutical research has targeted the “amyloid cascade hypothesis,” but this has not produced meaningful results, leading researchers to focus now on other characteristics of the disease and on multitarget approaches. This review aims to evaluate some new treatments that are being developed and studied. Among these are new treatments based on peptides, which have high selectivity and low toxicity; however, these compounds have a short half-life and encounter challenges when crossing the blood-brain barrier. The present review discusses up-and-coming peptides tested as treatments and explores some nanotechnological strategies to overcome the downsides. These compounds are promising, as they not only act on the symptoms but also aim to prevent progressive neuronal loss.pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-9558-4787pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-6849-6001pt_BR
dc.contributor.emailmailto:mmortari@unb.brpt_BR
Collection(s) :Artigos publicados em periódicos e afins

Affichage abbrégé " class="statisticsLink btn btn-primary" href="/handle/10482/44333/statistics">



Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.